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Abstract. Neonatal hypoxic-ischemic (HI) brain injury causes 
severe brain damage in newborns. Following HI injury, rapidly 
accumulating oxidants injure neurons and interrupt ongoing 
developmental processes. The antioxidant, sodium pyruvate, 
has been shown to reduce neuronal injury in neonatal rats under 
conditions of oxygen glucose deprivation (OGD) and HI injury. 
In this study, we evaluated the effects of ethyl pyruvate (EP) and 
insulin-like growth factor-I (IGF-I) alone or in combination in 
a similar setting. For this purpose, we used an in vitro model 
involving primary neonatal rat cortical neurons subjected to 
OGD for 2.5 h and an in vivo model involving unilateral carotid 
ligation in rats on post-natal day 7 with exposure to 8% hypoxia 
for 2.5 h. The cultured neurons were examined by lactate 
dehydrogenase (LDH) and cell viability assays. For the in vivo 
experiments, behavioral development was evaluated by the foot 
fault test at 4 weeks of recovery. 2,3,5-Triphenyltetrazolium chlo-
ride monohydrate and cresyl violet staining were used to evaluate 
HI injury. The injured neurons were Fluoro-Jade B-labeled, 
new neuroprecursors were double labeled with bromodeoxy-
uridine (BrdU) and doublecortin, new mature neurons were 
BrdU-labeled and neuronal nuclei were labeled by immunofluo-
rescence. Under conditions of OGD, the LDH levels increased 
and neuronal viability decreased. Treatment with 0.5 mM EP or 
25 ng/ml IGF-I protected the neurons (P<0.05), exerting addi-
tive effects. Similarly, either the early administration of EP or 
delayed treatment with IGF-I protected the neonatal rat brains 
against HI injury and improved neurological performance and 
these effects were also additive. This effect may be the result 
of reduced neuronal injury, and enhanced neurogenesis and 
maturation. On the whole, our findings demonstrate that the 
combination of the early administration of EP with delayed 
treatment with IGF-I exerts neuroprotective effects against HI 
injury in neonatal rat brains.
Introduction
Immature brains are known to be exceedingly sensitive to 
oxidative stress, due to high levels of unsaturated fatty acids, a 
high rate of oxygen consumption, low concentrations of antioxi-
dants, a high content of metals catalyzing free radical formation 
and a large proportion of sensitive immature cells (1-3). This 
sensitivity undoubtedly contributes to the severe neuronal 
damage observed following hypoxic-ischemic encephalop-
athy (HIE) in newborns (3). HIE occurs in 0.1-0.2% of term or 
near-term infants, among whom approximately 20% die and 
up to 40% of the survivors often suffer devastating disabilities, 
such as cerebral palsy, mental retardation and epilepsy (4-7). 
Thus, the reduction of damaging oxidants in neonatal brains 
following hypoxic-ischemic (HI) injury is one of the main 
therapeutic goals for the effective treatment of HIE.
Compared with adult patients, infants have a poorer prog-
nosis as HI injury not only leads to injury to neuronal cells, but 
it also disrupts ongoing brain development. Insulin-like growth 
factor-I (IGF-I) is an essential trophic factor for neuronal 
proliferation and differentiation (8,9). Its potential neuropro-
tective effects against HI injury in immature brains have been 
evaluated in fetal sheep (10) and neonatal rat models (11). In 
the rat model, although the exogenous administration of IGF-I 
was shown to exert neuroprotective effects and to improve 
long-term neurological function (11), only a 40% reduction in 
brain injury was achieved at 3 days of recovery when IGF-I 
was administered by intraventricular injection immediately 
following HI injury (11). On the other hand, the delayed 
subcutaneous administration of IGF-I (24 and 48 h post-
injury) has been shown to significantly increase the volume of 
surviving brain tissue and to improve behavioral development 
at 2 months of age (19). These time-dependent neuroprotective 
effects may be attributed to the suppression of IGF-I activity 
due to increased levels of oxidative stress in the acute phase 
of injury. Therefore, we hypothesized that the reduction of 
the levels of oxidative stress may enhance the neuroprotective 
effects of IGF-I.
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Sodium pyruvate (SP) is a substrate of the tricarboxylic acid 
cycle and an extracellular antioxidant (12,13). In a previous study, 
we found that SP improved the survival of primary cortical 
neurons under conditions of oxygen glucose deprivation (OGD) 
and, when administered 30 min after HI injury, it reduced HI 
injury to neonatal rat brains and improved long-term behav-
ioral recovery (14). Compared with SP, ethyl pyruvate (EP) is 
a more stable lipophilic ester derivative of pyruvate and has 
been proven to reduce HI injury to neonatal brains through 
anti-cell death and anti-inflammatory mechanisms (15). As EP 
has a longer half-life and fewer side-effects, we hypothesized 
that the early administration of EP may improve the protective 
effects of IGF-I against HI in immature brains. In this study, 
we examined this hypothesis in vitro using a model of ODG, as 
well as in vivo using a model of neonatal rat HI injury.
Materials and methods
Primary cortical neuron culture. The animal experiments 
were approved by the Ethics Committee of Indiana University 
School of Medicine, Indianapolis, IN, USA. The cultured 
primary neurons were derived from newborn Sprague-Dawley 
rats (10-12 pups) as previously described (6). Briefly, after 
removing the meninges, the cortical tissue was minced and 
maintained in Dulbecco's modified Eagle's medium (DMEM) 
at 4˚C. An aliquot of 0.25% trypsin (15050-065; Invitrogen, 
Carlsbad, CA, USA) and DNase (DN25; Sigma, St. Louis, MO, 
USA) was added to the tissue and incubated for 15 min at 37˚C 
to produce a single cell suspension. Following centrifugation, 
the cells were resuspended in neurobasal (NB) medium (10888; 
Gibco/Life Technologies, Grand Island, NY, USA) supplemented 
with 2% B-27 (17504-044; Invitrogen), 0.5 mM glutamine 
(25030-081; Gibco), 100 U/ml penicillin and 100 µg/ml strepto-
mycin. The cells were plated into poly-L-lysine-coated (P1399; 
Sigma) dishes at 5x105/ml. The culture medium was changed 
at 24 h and 4 days in vitro (DIV) and fibroblast growth factor 
(FGF; 5 ng/ml final concentration; F0291; Sigma) was added 
to the culture medium. The cells were ready to use at 6-7 DIV.
OGD. On day 7, the cultured primary cortical neurons were 
gently washed with phosphate-buffered saline (PBS) and the 
medium was then changed to glucose-free DMEM (11965; Gibco) 
before the cells were placed in a humidified chamber gassed with 
95% N2/5% CO2 at 37˚C. The medium of the control cells was 
changed to DMEM with glucose (11966; Gibco) and the cells 
were kept in a regular incubator (5% CO2 and 21% O2, 37˚C). 
After 2.5 h, the cells were removed from the hypoxic chamber 
to the regular incubator after changing the medium back to NB 
medium and treated with EP (0.5 mM; E47808; Sigma) and/or 
IGF-I (25 ng/ml; 100-11; Peprotech, Inc., Rocky Hill, NJ, USA).
Lactate dehydrogenase (LDH) release and MTT assay. Cell 
injury was assessed by measuring the amount of LDH released 
into the culture medium using a cytotoxicity detection kit 
(G1780; Promega Corp., Madison, WI, USA) according to the 
manufacturer's instructions. Briefly, 50 µl of culture medium 
were mixed with 50 µl substrate followed by incubation in the 
dark at 37˚C for 30 min. Subsequenlty, 50 µl stop solution were 
added and the absorbance was measured at 490 nm using a 
microplate reader (M2003; Sigma).
Cell viability was monitored by MTT colorimetric assay 
(M2003; Sigma). A total of 10 µl MTT was added to 500 µl 
of cell culture medium followed by incubation at 37˚C for 4 h. 
After discarding the medium, 500 µl dimethyl sulfoxide were 
added and the absorbance at 570 nm was recorded using a 
microplate reader (M2003; Sigma).
Model of neonatal HI injury. Briefly, 7-day-old Sprague-Dawley 
rat pups (8 per litter, weighing 13-18 g) were anesthetized with 
a mixture of isoflurane (3-4% for induction and 2% for main-
tenance) and 30% O2/70% N2. The left carotid artery of each 
pup was exposed and ligated with 6-0 surgical silk. After a 2-h 
recovery period, the pups were placed in 2-litre airtight and 
watertight glass flasks, submerged in a 37.0˚C water bath, and 
exposed to a humidified mixture of 8% O2 and 92% N2. After 
2.5 h of hypoxia, the pups were then returned to their dams 
and received the different treatments. The environmental 
temperature following HI injury was 25˚C. EP was adminis-
tered 30 min after HI injury by intraperitoneal (i.p.) injection 
(25 mg/kg; E47808; Sigma) and IGF-I was administered 24 h 
after HI injury by subcutaneous (s.c.) injection (3 mg/kg; 
100-11; Peprotech, Inc.). The same volume of normal saline 
was injected and served as the vehicle. The sham-operated 
group underwent the same surgical procedure apart from 
carotid artery ligaton and exposure to hypoxia.
Foot fault test. Foot-fault tests were performed at 4 weeks of 
recovery as previously described (14). The rats were placed on an 
elevated stainless steel wire (diameter, 0.4 cm) grid (1 m above 
the floor with 3 cm2 holes). Each pup was placed on the grid and 
the number of foot faults was counted out of 50 steps for fore-
limbs or hindlimbs. A foot fault was defined as when the animal 
misplaced a forelimb or hindlimb and the paw fell between the 
grid bars. The examiners were blinded from the study design.
2,3,5‑Triphenyltetrazolium chloride monohydrate (TTC) staining. 
TTC staining was performed as previously described (16). At 
48 h after HI injury, the rat brains were removed after sacrifice 
and immediately sectioned coronally into 6 slices (2-mm-thick) 
in a brain matrix (RBM-4000C Rodent Brain Matrix, Adult Rat, 
Coronal Sections; ASI Instruments, Inc. Warren, MI, USA). The 
brain slices were incubated in TTC (T8877; 1%; Sigma) at 37˚C 
for 10 min and fixed in 10% buffered formalin. Images of the 
sections were acquired using a digital camera and the survival 
area was measured using ImageJ software. For each brain, the 
surviving area of brain tissue was calculated as the ratio of the 
area of ipsilateral TTC-stained tissue (non-ischemic) to the area 
of contralateral TTC-stained tissue.
Sample preparation. At 3, 6, 12, 24, 48, 72 h, 7 days or 
4 weeks after HI injury, the animals were deeply anesthe-
tized with an overdose of sodium pentobarbital and then 
perfused transcardially with cold 0.9% saline, followed by 
4% paraformaldehyde (PFA) in PBS. The brains were removed 
and post-fixed in PFA overnight, then cryoprotected with 
30% sucrose for 48 h. Serial coronal sections (30 µm) were cut 
and stored at -20˚C.
Cresyl violet staining. For cresyl violet staining, the sections 
obtained on day 7 were incubated with cresyl violet for 30 min 
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at 37˚C. Ethanol solution differentiated the stain. The sections 
were then rinsed with distilled water and fully air dried.
Fluoro‑Jade B (FJB) staining. FJB staining was performed 
as previously described (16). For FJB staining, the sections 
obtained at 3-72 h were incubated with a solution of 
0.06% potassium permanganate for 30 min, and then incubated 
with a 0.0004% solution of FJB (AG310; Millipore, Billerica, 
MA, USA) and 4',6-diamidino-2-phenylindole (DAPI; Sigma) 
for 20 min. The sections were then rinsed with distilled water 
and fully air dried. The number of FJB-positive neurons in 
3 sections was determined in the ipsilateral hippocampus that 
was affected by HI injury.
3‑Bromodeoxyuridine (BrdU) staining. For BrdU labeling, 
the rat pups were administered daily i.p. injections (50 µg/g 
in 0.9% saline; Sigma) from day 1 to day 7 post-HI injury. 
BrdU+ cells were detected at 72 h (P10) or 4 weeks (P35) 
after surgery using an antibody against BrdU (OBT0030, 
rat; 1:400; Accurate Chemical & Scientific Corp., Westbury, 
NY, USA). Briefly, the brain sections were incubated with 
blocking solution (0.1% Triton X-100, 1% bovine serum 
albumin, and 5% normal goat serum in PBS) for 1 h at 
room temperature, followed by an overnight incubation with 
primary antibody (anti-rat BrdU; 1:400, OBT0030; Accurate 
Chemical & Scientific Corp.) at 4˚C. The sections were then 
washed with PBS and incubated with a secondary antibody 
(Jackson ImmunoResearch Laboratories, Inc., West Grove, 
PA, USA) at room temperature for 1 h. After being treated 
with DAPI for 2 min, the sections were washed with PBS and 
mounted on slides with Fluoromount G (Cat. no. 17984-25; 
Electron Microscopy Sciences, Hatfield, PA, USA).
Immunofluorescence staining. The differentiation states of 
the BrdU+ neurons were determined by co-labeling with an 
antibody against doublecortin (DCX) (AB2253, guinea pig; 
1:1,500; Millipore) at 72 h following HI injury (P10) or with an 
antibody against neuronal nuclei antigen (NeuN) (MAB377, 
mouse; 1:100; Millipore) at 4 weeks following HI injury (P35).
Following immunostaining, the sections were analyzed 
by light microscopy at a magnification, x20 using an inverted 
microscope (Zeiss Axiovert 200M; Carl Zeiss, Göttingen, 
Germany) interfaced with a digital camera (Zeiss Axion 
Cam MRc5; Carl Zeiss) controlled by a computer.
Statistical analysis. Data are presented as the means ± standard 
error of the mean. Statistical differences between >2 groups 
were analyzed by using a one-way analysis of variance followed 
by the Turkey multiple comparison test. A value of P<0.05 was 
considered to indicate a statistically significant difference.
Results
Neuroprotective effects of the combination of EP and IGF‑I in 
cultured neurons under conditions of OGD. To examine the 
neuroprotective effects of EP and/or IGF-I against HI injury, 
we first examined the degree of neuronal injury by LDH assay 
and cell viability (by MTT assay) in the absence or presence 
of increasing concentrations of EP or IGF-I under conditions 
of OGD (17). Under conditions of OGD, the LDH levels were 
increased in the culture medium and the MTT levels were 
decreased in the cell lysate at 24 h of reoxygenation, suggesting 
neuronal injury under oxidative stress (Fig. 1A and B). As the 
concentration of EP or IGF-I increased in the culture medium, 
the LDH levels decreased and the MTT levels increased 
(Fig. 1A and B), both in a dose-dependent manner, indicating 
a decrease in neuronal injury and an increase in neuronal cell 
viability. The neuroprotective effects were the most prominent 
when EP (0.5 mM) was combined with IGF-I (25 ng/ml) as 
compared to treatment with EP or IGF-I alone (Fig. 1C).
EP and IGF‑I promote long‑term behavioral development 
following HI injury. We then evaluated the neuroprotective 
effects of EP and/or IGF-I in a commonly used neonatal 
rat model of HI injury (18). At 48 h of recovery, EP began 
to show protective effects against HI injury at the dose of 
25 mg/kg (administered at 30 min after HI injury), indi-
cated by an increase in the volume area of surviving brain 
tissue (Fig. 2A). We selected a previously published IGF-I 
(3 mg/kg, 24 h post HI) treatment dose and schedule (19) to 
evaluate the neuroprotective effects of the two treatments.
Compared with the sham-operated rats, HI injury to the 
ipisilateral section of the brain resulted in weight loss within 
24 h (Fig. 2B). While the rats in the sham-operated group 
gained approximately 13% of body weight the following day, 
the rats in the treated groups gained more weight over the 
same time period, with the combined treatment group gaining 
the most weight (Fig. 2B).
We employed a foot fault test to compare the senso-
rimotor behavior of the rats in the different treatment groups 
with that of the rats in the sham-operated group at 4 weeks 
of recovery (Fig. 2C and D). When the total number of foot 
faults per 50 steps was recorded within 5 min, the rats in the 
vehicle-treated group showed a significantly increased number 
of foot faults compared with the rats in the sham-operated 
group (right forelimb, Fig. 2C; right hindlimb, Fig. 2D). 
However, treatment with EP or IGF-I decreased the number 
of foot faults, and combination treatment with EP and IGF-I 
resulted in a further reduction in the number of both right fore-
limb and hindlimb foot faults compared with either treatment 
alone.
Neuroprotective effects of the combination of EP and IGF‑I 
in vivo. At 48 h of recovery, the amount of surviving brain 
tissue in the EP + IGF-I group was 84.2±9.0%, significantly 
higher than that with EP treatment alone (71.8±14.2%) or 
IGF-I treatment alone (68.8±10.3%). These neuroprotective 
effects were additive and not transient (Fig. 3A and B). At 
7 days of recovery, the amount of surviving brain cortex tissue 
in the EP + IGF-I group was 89.7±6.8%, significantly higher 
than that with EP treatment alone (73.2±1.4%) or IGF-I treat-
ment alone (70.0±8.6%). The amount of surviving tissue in the 
hippocampus in the EP + IGF-I group was 78.0±9.6%, signifi-
cantly higher than that with EP treatment alone (58.3±1.2%) or 
IGF-I treatment alone (58.5±9.3%) (Fig. 3C and D). Therefore, 
treatment with EP (25 mg/g, 30 min post-HI injury) in combi-
nation with IGF-I (3 mg/kg, 24 h post-HI injury) exerted 
neuroprotective effects against HI injury, as indicated by 
the increase in the volume of surviving brain tissue at 48 h 
(Fig. 3A and B) and 7 days (Fig. 3C and D) of recovery.
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Treatment with EP and IGF‑I decreases apoptosis in the damaged 
hippocampus following HI injury. The increase in the volume of 
surviving tissue in the brain may have been a result of a reduced 
number of injured neurons. To clarify this, we labeled the injured 
neurons with FJB beginning at 3 h after injury and for up to at 
least 7 days. Fig. 4 illustrates the distribution of FJB+ cells in the 
hippocampus. The FJB+ neurons were detected at 3 h of recovery 
and reached peak numbers from 48-72 h (data not shown). At 
72 h of recovery, HI injury to the neonatal brain increased the 
number of FJB+ cells both in the dentate gyrus (DG) and cornu 
ammonis 3 (CA3) region of the hippocampus (Fig. 4A-D). At a 
higher magnification, the FJB+ neurons displayed distinct apop-
totic nuclei with either a condensed or fragmented morphology. 
Compared with the vehicle-treated group, the numbers of FJB+ 
neurons were significantly decreased by EP treatment or IGF-I 
treatment, whereas combined treatment with EP and IGF-I led to 
a further decrease in the number of FJB+ neurons compared to 
the groups treated with EP or IGF-I alone (Fig. 4E).
HI injury promotes neuronal cell proliferation. To determine the 
effect of HI injury on neurogenesis, we labeled proliferating cells 
with BrdU during the first 7 days following HI injury. Within the 
hippocampus of the rats in the sham-operated group, the majority 
of BrdU+ cells was distributed in the subgranular zone (SGZ), 
where neural stem cells or immature neurons reside (Fig. 5). In 
comparison, the BrdU+ cells in the rats in the group subjected 
to HI injury were not confined to the SGZ, but were scattered 
around the entire DG, suggesting that newborn cells had migrated 
to other locations. Overall, the number of BrdU+ cells in the DG 
of the rats in the group subjected to HI injury was double that of 
the cells in the DG of rats in the sham-operated group (Fig. 5C).
Treatment with EP and IGF‑I promotes neurogenesis in the 
damaged hippocampus following HI injury. To examine the 
neuronal differentiation of BrdU+ cells, we double labeled 
BrdU+ cells with either DCX, a marker for immature neurons, 
or NeuN, a marker for mature neurons. At 72 h post-HI injury, 
Figure 1. Ethyl pyruvate (EP) and insulin-like growth factor-I (IGF-I) protect primary cortical neurons against oxygen glucose deprivation (OGD). (A) EP 
reduced OGD-induced neuronal cell injury in a dose-dependent manner, as indicated by the reduced lactate dehydrogenase (LDH) levels in the culture medium 
and the increased MTT levels in the cell lysates at 24 h of reoxygenation. *P<0.05 and **P<0.01, compared with OGD alone (n=6). (B) IGF-I reduced OGD-
induced neuronal injury in a dose-dependent manner, as indicated by the reduced LDH levels in the culture medium and the increased MTT levels in the cell 
lysates at 24 h of reoxygenation. *P<0.05 compared with OGD alone (n=6). (C) Combined treatment with EP (0.5 mM) and IGF-I (25 ng/ml) further reduced 
OGD-induced neuronal cell injury than with each treatment alone. *P<0.05 as indicated (n=6).
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Figure 2. Ethyl pyruvate (EP) and insulin-like growth factor-I (IGF-I) promote long-term behavioral development following hypoxic-ischemic (HI) injury. 
(A) EP exerted neuroprotective effects in a dose-dependent manner (30 min after HI injury) *P<0.05 as indicated (n=6). (B) Body weight following HI injury. 
Rat pups were treated with EP 30 min after HI injury or with IGF-I 24 h after HI injury or with both agents. The y-axis represents the percentage changes in 
body weight as compared to the weight before HI injury. *P<0.05 compared with the sham-operated group, #P<0.05 compared with other the 3 groups subjected 
to HI injury (n=8). Foot fault tests were performed at 4 weeks of recovery (P35). Number of foot faults of (C) right forelimbs or (D) right hindlimbs per 50 steps 
were counted within 5 min. *P<0.05 compared with sham-operated group, #P<0.05 compared with other 3 groups subjected to HI injury (n=8). L, left; R, right.
Figure 3. Ethyl pyruvate (EP) and insulin-like growth factor-I (IGF-I) reduce hypoxic-ischemic (HI) injury to neonatal rat brains. (A) Representative 2,3,5-tri-
phenyltetrazolium chloride-stained brain sections from 9-day-old rats (48 h after HI injury), treated with the vehicle, EP (25 mg/kg, 30 min post HI), IGF-I 
(3 mg/kg, 24 h post-HI injury) or a combination of the EP and IGF-I. (B) Quantification of the amount of surviving brain tissue following the different treatments. 
*P<0.05 as indicated (n=8). (C) Representative cresyl violet-stained sections from 14-day-old rats (7 days post-HI injury). (D) Quantification of the amount of 
surviving cortical or hippocampal tissue. *P<0.05 compared with the other 3 groups subjected to HI injury (n=8). L, left; R, right.
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the number of BrdU+DCX+ cells in the group subjected to HI 
injury was increased compared to that of the rats in the sham-
operated group (Fig. 6). Although mainly distributed in the 
SGZ of the rats in the sham-operated group, the BrdU+DCX+ 
cells were also distributed in the granule cell layer (GCL) in the 
group subjected to HI (Fig. 6A, panel d), indicating that more 
BrdU+DCX+ cells may have migrated. Although the numbers of 
the BrdU+DCX+ cells in the group treated with EP were similar 
to those of the vehicle-treated group, the numbers were mark-
edly increased in the IGF-I-treated group and the combined 
treatment group, indicating that IGF-I, but not EP, stimulated 
neurogenesis (Fig. 6B). At 4 weeks post-injury, the number of 
NeuN+BrdU+ neurons was also elevated (Fig. 7) in the group 
subjected to HI compared to the sham-operated group. Of 
note, the increase in the number of DCX+ cells (Fig. 6B) and 
NeuN+ cells (Fig. 7C), showing a similar pattern among the 
treatment groups, suggesting that IGF-I not only stimulated 
neurogenesis, but also neuronal survival and differentiation.
Figure 4. Combined treatment with ethyl pyruvate (EP) and insulin-like growth factor-I (IGF-I) decreases hypoxic-ischemic (HI) injury-induced neuronal cell 
death in the hippocampal cornu ammonis 3 (CA3) region. (A) At 72 h post-HI injury, the injured hippocampal neurons were identified by Fluoro-Jade B (FJB) 
staining (green) and the nucleus were stained with 4',6-diamidino-2-phenylindole (DAPI) (blue). (B) High magnification view [squares in (A)] showing the 
morphology of degenerating hippocampal neurons (green). (C) Cell nuclei were identified by DAPI staining. (D) Merged image of (B) and (C). (E) Quantification 
of FJB+ cells in the ipsilateral hippocampus. *P<0.05 as indicated (n=3-6 per group).
Figure 5. Hypoxic-ischemic (HI) injury promotes neuronal cell proliferation. (A) HI injury promoted cell proliferation in the hippocampus. Proliferating 
cells were identified by bromodeoxyuridine (BrdU) immunostaining (green) 72 h post-HI injury. The structure of the dentate nucleus is shown by the align-
ment of nuclei stained with 4’,6-diamidino-2-phenylindole (blue). (B) High magnification view of the square in (A) showing the distribution of proliferating 
cells. (C) Quantification of proliferating cells in the different subregions of the hippocampus. *P<0.05 compared with sham-operated group (sham; n=6). ML, 
molecular layer; GCL, granule cell layer; SGZ, subgranular zone.
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Discussion
HI injury results in severe damage to immature brains as it 
disturbs multiple developmental events in addition to normal 
brain functions. Compared with the adult brain, neonatal 
brains often display different forms of cell death (20) and 
different responses to therapeutic interventions (21,22). One of 
the underlying causes for these differences is the inability of 
the immature brains to handle the rapidly accumulating levels 
of oxidative stress immediately following HI injury (1-3). In 
fact, treatments with antioxidants provide beneficial effects 
as has been shown in animal models of HI injury (14,23,24). 
While the removal of oxidants only offers temporary relief, 
resumption of the normal developmental process is equally 
urgent for the young brain. In contination of our previous study 
on the beneficial effects of SP (14), in this study, we focused on 
the neuroprotective effects of EP and IGF-I.
Our choice of this combination was based on the following 
considerations: first, SP provided long-term neuroprotective 
effects to immature brains following HI, but it is not suitable for 
clinical use due to its short half-life, instability and side-effects 
in adults (25). It has been shown that EP, a more stable and 
lipophilic derivative of pyruvic acid (25), exerts neuroprotective 
effects on cortical neurons equal to those of SP under conditions 
of OGD. More importantly, EP (25 mg/kg) reduced brain injury 
to the same extent (~20%) as SP (500 mg/kg), but at a much lower 
dose (data not shown). Due to its anti-inflammatory effects (26), 
EP is evidently the better choice for further investigation. These 
positive results showing the neuroprotective effects of EP, are 
contrast to those of another study demonstrating the negative 
effects of neuroprotectants (27). The results in that case showed 
no reduction in the severity of infarction in an in vivo rat model, 
despite the fact that the model used was similar to the one we 
used. The main differences between the studies were that the rats 
were a different strain (Wistar compared to Sprague-Dawley), 
the doses were lower than our doses (10 and 40 mg/kg compared 
to our most effective doses at 25 and 50 mg/kg) and the expo-
sure to hypoxia was shorter (50 min compared to 150 min). The 
outcome was scored only in terms of macroscopic brain injury 
so there is a possibility that some effects were missed. The exact 
reasons for these different results warrant further investigation, 
as it is important that these effects be reproducible in different 
model systems if their potential for clinical treatment is to be 
fulfilled (27).
Second, IGF-I is a pleiotrophic factor essential to the survival 
of immature neurons and maintenance of the high metabolism 
needed to fulfill developmental needs, such as neuronal migra-
tion, axon extension and synaptogenesis (28). Serum IGF-I 
levels have been shown to be decreased in human newborns 
suffering from HIE (29) and neuronal IGF-I mRNA (30) 
and IGF-I serum levels have been shown to be decreased in 
neonatal rat brains following HI injury (19,31). However, imme-
diate intraventricular (32) and intranasal delivery (33) was less 
effective than delayed subcutaneous delivery (24 and 48 h) 
in terms of the reduction of the voluem of injured tissue and 
long-term behavioral recovery. This improvement with delayed 
treatment indicates that IGF-I is less effective during the acute 
phase when oxidative stress is at its highest. A similar result 
was observed in a study on rat oligodendrocyte progenitors, 
where delayed cell death caused by glutamate was prevented 
by both the immediate and late (16 h post-exposure) adminis-
tration of IGF-I, while cell proliferation was promoted (34). In 
Figure 6. Combined treatment with insulin-like growth factor-I (IGF-I) and ethyl pyruvate (EP) increases hypoxic-ischemic (HI) injury-induced neurogenesis. 
(A) High magnification view of the square in the hippocampus. Double immunostaining to identify the newborn neurons (panel a, merge) with doublecortin (DCX) 
immunostaining (panel b, red) and bromodeoxyuridine (BrdU) immunostaining (panel c, green) 72 h post-HI injury. Nuclei are stained with DAPI (panel d, blue). 
(B) Quantification of the number of newborn neurons (DCX+BrdU+). *P<0.05, **P<0.01 as indicated (n=6). 
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addition IGF-I reverse the loss in oligodendrocyte transcription 
factor-positive cells in white matter following HI injury (34). 
Therefore, combining IGF-I with early EP treatment to reduce 
oxidative stress may protect immature neurons against injury 
and assist their normal development.
The above hypothesis was supported by the results of the 
present study: early EP treatment combined with the delayed 
s.c. injection of IGF-I led to reduced neuronal cell death under 
conditions of OGD, and reduced damage to the neonatal brain 
due to HI injury, both in short-term and long-term experi-
ments. In the developing hippocampus, the DG is known to 
be more vulnerable to HI injury than the CA3 region (36). In 
this study, we found that neuronal cell death occurred both 
in the DG and CA3 regions, which may result from a longer 
exposure to hypoxia (2.5 h) than in other studies (usually 
<2 h) (35-37). At 72 h of recovery, treatment with EP and IGF-I 
alone reduced the number of injured neurons, while combined 
treatment further reduced the number of FJB+ neurons. These 
neuroprotective effects may be a result of their complimentary 
neuroprotective actions. IGF-I promotes neuronal cell survival 
by activating the key survival signaling kinase, Akt (38), 
whereas EP scavenges free radicals and reduces inflammatory 
reactions (15).
Apart from promoting neuronal cell survival, IGF-I also 
stimulates neurogenesis (39,40). Unlike adult brains, to which 
traumatic brain injury mainly induces the proliferation of 
reactive astrocytes (41), HI injury to neonatal mouse brains 
promotes the proliferation of multiple cell types, including 
microglia, endothelial cells, oligodendrocytes and neurons (42). 
Following HI injury, we found that the BrdU+ cells were mainly 
distributed in the granular and molecular neuronal cell layers 
of the hippocampus, which contain neurons from secondary 
neurogenesis (43). To characterize neurogenesis and differen-
tiation following HI injury, we double stained BrdU+ cells with 
DCX, a marker for immature neurons, or NeuN, a marker for 
mature neurons. At 3 days and 4 weeks following HI injury, a 
parallel trend emerged: while EP alone did not have much of 
an effect, IGF-I or combined treatment with both EP and IGF-I 
resulted in a similar increase in the number of BrdU+DCX+ 
immature neurons, as well as in the number of BrdU+NeuN+ 
mature neurons. In addition, a greater number of BrdU+DCX+ 
cells had migrated into the GCL and had likely become 
incorporated into the neuronal network, as demonstrated by 
improved motor coordination at 4 weeks of recovery.
In conclusion, the findings of this study demonstrate that 
combining early EP administration with the delayed s.c. injec-
Figure 7. Combined treatment with insulin-like growth factor-I (IGF-I) and ethyl pyruvate (EP) promotes the maturation of newborn neurons. (A) Matured neurons 
born in the hippocampus. Double immunostaining to identify the matured neurons (panel a, merge) with neuronal nuclei antigen (NeuN) (panel b, red) and bro-
modeoxyuridine (BrdU) (panel c, green) at 4 weeks post-hypoxic-ischemic (HI) injury. Nuclei are stained with DAPI (blue; panel d). (B) High magnification view 
of the square in the hippocampus to show the mature neurons (panel a, merge) with NeuN antibody (panel b) and antibody against BrdU (panel c) 4 weeks post-HI 
injury. Nuclei are stained with DAPI (blue;panel d). (C) Quantification of the number of newborn neurons (NeuN+BrdU+). *P<0.05, **P<0.01 as indicated (n=6). 
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tion of IGF-I exerts neuroprotective effects on immature neurons 
under conditions of OGD and following HI injury. These effects 
were likely the result of a reduction in neuronal cell death and 
an increase in neurogenesis/differentiation following HI injury.
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